高龄抑郁症患者血清BDNF、SP、IL-18表达水平分析

目的研究高龄抑郁症患者血清BDNF、SP、IL-18表达水平及临床意义。方法选择2016年7月～2018年1月在本院就诊的128例高龄抑郁症患者作为研究对象,根据抑郁自评量表(Self-rating depression scale,SDS)评分将其分为轻度抑郁组(40例)、中度抑郁组(45例)、重度抑郁组(43例);另选择40例体检健康者作为对照组。比较四组的血清BDNF、SP、IL-18水平和汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、生活质量量表(WHOQOL-BREF)。结果对照组的血清DBNF水平显著高于中度、重度抑郁组,SP、IL-18水平显著低于轻度、中度、重度抑郁组,差异均有统计学意义(P0.05);对照组与轻度抑郁组的血清DBNF水平比较,差异无统计学意义(P0.05)。对照组的HAMD、HAMA评分显著低于轻度、中度、重度抑郁组,差异均有统计学意义(P0.05)。对照组的WHOQOL-BREF总分显著高于轻度、中度、重度抑郁组,差异均有统计学意义(P0.05)。结论血清BDNF、SP、IL-18水平对预测高龄患者抑郁症程度可能有一定的临床价值。     

脑出血患者血清脑源性神经营养因子与痴呆的相关性分析

目的探讨脑出血患者血清脑源性神经营养因子(BDNF)与痴呆的相关性。方法选取180例脑出血患者,出院后6个月根据认知功能评分分为血管性认知功能障碍组(VCI)60例,其中血管性痴呆组(VD)22例,非痴呆型血管性认知功能障碍组(VCIND)38例;对照组为无认知障碍者120例。入院后及出院后6个月采用酶联免疫吸附法(ELISA)检测血清BDNF水平,分析其与认知功能障碍的相关性。采用ROC曲线分析BDNF对VCI发生的预测价值。结果VCI组年龄、NIHSS评分、出血量、出血部位、Hcy水平及BDNF水平与对照组比较差异有统计学意义(P<0.05)。多因素分析示高龄、NIHSS评分高、大量出血、脑叶出血、Hcy水平升高及BDNF水平降低是脑出血患者发生VCI的危险因素(P<0.05)。出院时6个月VCIND组与对照组MMSE评分、BDNF水平均高于入院时(P<0.05)。出院后6个月VD组BDNF水平高于入院时(P<0.05)。出院后6个月3组MMSE评分比较差异有统计学意义(P<0.05),两两比较,VD组与VCIND组MMSE评分低于对照组(P<0.05),VD组MMSE评分低于VCIND组(P<0.05)。入院时及出院后6个月3组BDNF水平比较差异有统计学意义(P<0.05),两两比较,入院时及出院后6个月VD组与VCIND组BDNF水平均低于对照组(P<0.05),VD组BDNF水平低于VCIND组(P<0.05)。出院后6个月BDNF水平与MMSE评分呈正相关(P<0.05)。BDNF预测VD及预测VCIND的AUC面积分别为0.749、0.704,均>0.7,灵敏度分别为84.2%、85.9%,特异度分别为80.9%、80.6%。结论脑出血患者血清BDNF水平与出血后VCI的发生相关,随着BDNF水平的降低,VCI严重程度随之增加,且入院后血清BDNF水平可以预测VCI的发生,特别是VD发生的标记物之一,临床上血清BDNF水平低的患者需引起重视。     

MMSE和MoCA在不同类型轻度认知障碍筛查中的应用

目的探讨简易精神状态量表(MMSE)和蒙特利尔认知评估量表(Mo CA)在遗忘型轻度认知障碍(a MCI)和轻度血管性认知障碍(m VCI)患者中的应用。方法从2012年3月至2015年3月本科收治的年龄60~80岁近200例患者中筛选出a MCI组42例,m VCI组50例,采用分组对照研究,所有患者经过临床痴呆评定量表(CDR)和日常生活能力量表(ADL)评估与接受Mo CA量表中文版和MMSE量表进行认知功能评估。Mo CA与MMSE的评估间隔1h以上,在同一天进行。结果两组患者性别构成比、年龄及受教育程度间差异均无统计学意义(P>0.05)。MMSE量表测评两组间差异无统计学意义(P>0.05)。两组间MMSE分项比较,除a MCI组延迟回忆得分低于m VCI组(P<0.05)外,其余各分项得分无显著性差异(P>0.05)。m VCI组患者Mo CA总分较a MCI组水平低,差异有统计学意义(P<0.05)。两组间Mo CA分项比较,m VCI组视空间执行功能、注意力与计算各项得分低于a MCI组,差异有统计学意义(P<0.05)。a MCI组延迟回忆得分低于m VCI组,差异有统计学意义(P<0.05)。余各分项得分两组间无显著性差异(P>0.05)。m VCI组患者在交替连线、立方体画图及指针得分均低于a MCI组,差异有统计学意义(P<0.05)。相关性分析显示MMSE与Mo CA评分呈正相关关系,a MCI患者中相关系数为0.861,m VCI患者中相关系数为0.762,差异均有统计学意义(P<0.05)。结论 m VCI患者存在包括视空间执行功能、注意力及计算力等多个领域认知功能的损害,与a MCI患者相比,执行功能受损更明显。Mo CA是筛查a MCI及m VCI的一个简便、有效的工具,敏感性高于MMSE,尤其适于对m VCI患者的早期筛查。     

散发性阿尔茨海默病患者血清脑源性神经营养因子的测定及临床意义

目的探讨散发性阿尔茨海默病(sporadic Alzhei mer disease,SAD)患者血清脑源性神经营养因子(brain-derived neurotrophic factor,BDNF)变化及其临床意义。方法选择2004-11—2005-10作者医院门诊及住院SAD患者43例,其中轻度痴呆18例,中度痴呆19例,重度痴呆6例。对照组35例为同期体检者。采用酶联免疫吸附法(ELISA)测定外周血清BDNF水平。结果SAD组和对照组间性别(χ2=0.0042,P=0.9483)、年龄(t=0.38,P=0.7023)及血清BDNF水平(t=0.60,P=0.5528)差异均无统计学意义,轻、中、重度SAD组及对照组间血清BDNF水平比较亦无统计学意义(F=0.89,P=0.4526)。结论SAD患者外周血清BDNF水平无明显变化,血清BDNF水平不能作为SAD诊断的标志物,也不能反映痴呆的严重程度。     

首发精神分裂症患者血清miR-124、miR-381水平及其诊断价值

目的 探讨首发精神分裂症患者血清miR-124、miR-381水平及其诊断价值。方法 选取2019年5月至2021年5月于重庆市精神卫生中心入院治疗的91例首发精神分裂症患者为首发精神分裂症组，选取同期于我院健康体检的70名志愿者作为对照组。采用RT-qPCR检测两组受试者的血清miR-124、miR-381水平。采用阳性与阴性症状量表(PANSS)评估首发精神分裂症组患者的病情，并根据得分将患者分为轻度组(n=38)、中度组(n=29)、重度组(n=24)。采用Spearman相关分析首发精神分裂症患者血清miR-124、miR-381水平与PANSS得分的相关性。采用二项Logistic回归分析首发精神分裂症患者发病的影响因素。采用受试者工作特征(ROC)曲线分析血清miR-124、miR-381水平对重度首发精神分裂症的诊断价值。结果 首发精神分裂症组患者的血清miR-124水平低于对照组，miR-381高于对照组，差异均有统计学意义(t=7.022、11.192;P均<0.01)。中度组、重度组的血清miR-124水平低于轻度组，miR-381水平高于轻度组，差异有统计学...     

脑出血患者血清NSE、GFAP、BDNF水平变化与认知障碍相关性研究

目的探讨脑出血患者血清神经元特异性烯醇化酶(NSE)、胶质纤维酸性蛋白(GFAP)、脑源性神经营养因子(BDNF)水平变化与认知障碍相关性。方法选择急性自发性脑出血患者100例,入院时均给予相应治疗,并进行NSE、GFAP、BDNF检测。将100例患者依据是否发生认知障碍分为认知障碍组(57例)和无认知障碍组(43例)。并比较不同损伤水平(MMSE评分)患者三个指标之间的差异、计算三个指标与MMSE水平的相关性。结果认知功能障碍组患者血清NSE、GFAP水平均显著高于无认知功能障碍组,BDNF显著低于无认知功能障碍组(t=7.039,t=2.247,t=4.847,P0.01)。轻度损伤组、中度损伤组和重度损伤组间血清NSE、GFAP、BDNF水平存在显著差异(F=22.752,F=31.506,F=38.294,P0.01)。血清NSE、GFAP水平与MMSE评分正相关(r=0.641,r=0.604,P0.05),BDNF与MMSE评分负相关(r=0.582,P0.05)。结论脑出血患者血清NSE、GFAP、BDNF水平与脑出血患者卒中后认知功能障碍密切相关,可用于判断脑出血患者认知功能障碍的严重程度。     

动脉瘤性蛛网膜下腔出血并发脑血管痉挛患者血清血管内皮生长因子表达的变化

目的:探讨动脉瘤性蛛网膜下腔出血(SAH)并发脑血管痉挛(CVS)与血清血管内皮生长因子(VEGF)表达的关系.方法:27例动脉瘤性SAH患者为试验组(SAH组),再依据是否并发不同程度CVS分为:无CVS亚组(11例),轻度CVS亚组(9例)、中度CVS亚组(4例)和重度CVS亚组(3例);另设10名健康体检者为对照组.采用ELISA法检测血清VEGF水平.结果:SAH各时间点各组血清VEGF水平为①SAH组发病第1天起即明显高于对照组;②无CVS组不增高.SAH后第1、3、5、7天时血清VEGF水平为①轻度CVS组与中度CVS组相同时间点比较,差异无统计学意义;②重度CVS组明显高于轻度和中度CVS组.SAH后出现脑梗死患者血清VEGF水平明显高于未出现脑梗死患者.结论:SAH后出现CVS患者和出现脑梗死的患者血清VEGF水平明显增高,血清VEGF水平能反映脑血管痉挛的程度.     

腔隙性脑梗死患者血清维生素B12的检测及临床意义

目的 探讨腔隙性脑梗死患者血清维生素B12的检测及临床意义.方法 我院住院治疗的腔隙性脑梗死患者67例作为观察组,其中轻度32例,中度21例,重度14例.同时选择同时期我院住院治疗的菲脑梗死患者35例,作为对照组.对2组患者进行维生素B12和叶酸的检测.结果 观察组患者维生素B12和叶酸的检测结果均明显低于对照组(P＜0.05).重度腔隙性脑梗死患者的维生素B12和叶酸检测结果明显低于轻度和中度患者(P＜0.05),而轻度和中度腔隙性脑梗死患者的维生素B12和叶酸的检测结果比较,差异无统计学意义(P＞0.05).结论 血清维生素B12和叶酸的降低与腔隙性脑梗死的发生具有密切的关系,并且与患者的病情严重程度有关,值得临床重视.     

急性脑梗死患者神经功能缺损程度与血清H-FABP、CD62P水平的关系

目的 探讨急性脑梗死患者神经功能缺损程度与血清心型脂肪酸结合蛋白(H-FABP)、血小板α颗粒膜蛋白(CD62P)的关系。方法 选择本院收治的180例急性脑梗死患者为研究对象,将其分为轻度组、中度组、重度组3组,每组各60例,以同期体检健康者60例为对照组; 采用神经功能缺损评分量表(NIHSS评分)评定急性脑梗死患者神经功能缺损程度,通过酶联免疫吸附法(ELISA)检测各组血清神经功能缺损指标(NES、S100B)及H-FABP、CD26P水平,分析神经功能缺损程度与血清H-FABP、CD26P的关系。结果 急性脑梗死重度组与中度组NIHSS评分、NES及S100B水平均高于急性脑梗死轻度组,而中度组高于轻度组(P<0.01); 急性脑梗死组血清H-FABP、CD26P水平均高于对照组,急性脑梗死重度组与中度组高于急性脑梗死轻度组,而中度组血清H-FABP、CD26P水平高于轻度组(P<0.01); 急性脑梗死患者血清H-FABP、CD26P水平与神经功能缺损程度呈正相关。结论 急性脑梗死患者神经功能缺损程度与血清H-FABP、CD26P水平呈显著正相关,推测临床可参照血清H-FABP、CD26P水平来评估急性脑梗死患者神经功能缺损程度。     

腔隙性脑梗死患者脑微出血与血清同型半胱氨酸的相关性研究

目的分析腔隙性脑梗死患者脑微出血(CMB)与血清同型半胱氨酸(Hcy)的关系。方法选择急性腔隙性脑梗死患者85例,行MR SWI序列检查,根据CMB的数量,分为轻度(1个CMB)、中度(4个CMB)、重度CMB(10个以上CMB)组。记录患者临床特点,检测患者血清Hcy水平,分析Hcy与CMB的关系。结果 85例急性腔隙性脑梗死患者中,有CMB 35例(41.2%),其中轻度CMB组5例、中度CMB组10例、重度CMB组20例。血清同型半胱氨酸:CMB轻度组(14.2±3.1)μmol·L-1,中度组(17.5±2.6)μmol·L-1,重度组(19.0±3.8)μmol·L-1,方差分析发现,组间比较差异有统计学意义(F=4.579,P=0.019);CMB重度组血清Hcy水平高于轻度及中度组(P0.05);Spearm相关分析发现CMB病变程度与血清Hcy水平呈正相关(r=0.768,P0.001)。结论血清Hcy与腔隙性脑梗死患者的CMB有关,Hcy是CMB可能的危险因素;Hcy可以作为脑小血管病损伤的标志物之一,对CMB诊断和治疗有重要意义。     

BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls

Alzheimer's disease (AD) and normal pressure hydrocephalus (NPH) are common forms of dementia in the elderly. Recent findings have suggested an involvement of brain-derived neurotrophic factor (BDNF) in the pathogenesis of AD. BDNF is an endogenous protein involved in the maintenance of neuronal function, synaptic plasticity and structural integrity in the adult brain. BDNF serum and cerebrospinal fluid (CSF) concentrations were assessed by a sensitive ELISA in 27 AD patients in comparison to 9 NPH patients and 28 age-matched healthy controls (10 CSF samples). We found a significant decrease of BDNF serum concentration in AD (18.6ng/ml) and NPH patients (18.1ng/ml) as compared to healthy controls (21.3ng/ml; p=0.041/p=0.017). BDNF serum concentrations did not correlate with CSF levels, age or MMSE scores both in AD and NPH patients. In unconcentrated CSF samples, BDNF could be detected in AD patients in 8/27 cases (29.6%; mean of 4.6pg/ml), in NPH patients in 1/9 cases (11.1%; mean of 6.4pg/ml) and in the control subjects in 5/10 cases (50%; mean of 1.6pg/ml) with no significant differences as regards mean concentration and frequency of detectable BDNF in CSF. The decrease of BDNF serum levels in AD and NPH may reflect a lack of trophic support and thus contribute to progressive degeneration in both diseases. In contrast to serum, CSF seems to be no useful source to determine BDNF in AD or NPH because of too low concentrations. Further examinations have to follow to elucidate the potential sources and the meaning of reduced BDNF levels in the blood in AD and NPH.     

Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients

Brain-derived neurotrophic factor (BDNF) is an important member of the neurotrophin family of growth factors, abundant in the brain and periphery. Researchers have reported that serum BDNF levels in drug-free depressed patients are lower than those of healthy controls, and have proposed that these low levels might reflect a failure of neuronal plasticity in depression. In the present study, we investigated the effects of paroxetine, an SSRI, and milnacipran, an SNRI, on serum BDNF levels in depressed patients. Serum levels of BDNF were measured by ELISA before, 4 weeks, and 8 weeks after the start of treatment with antidepressants. Forty-two patients were randomly administered paroxetine (21 cases) or milnacipran (21 cases). A negative correlation was found between serum BDNF levels and baseline Ham-D scores. The response and remission rates for each drug were not significantly different. Serum BDNF levels in responders were significantly increased 2.6- and 1.8-fold 8 weeks after treatment with paroxetine or milnacipran, respectively. These results suggest that both drugs improve the depressive state by increasing BDNF levels.     

Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants

This study tried to investigate the relationships between serum brain-derived neurotrophic factor (BDNF) protein levels and major depressive patients and discuss the effects of antidepressants on the serum BDNF protein levels. A total of 218 participants, including 111 patients with major depression (91 women) and 107 healthy controls (65 women), were recruited in this study. Serum BDNF protein levels were measured using an ELISA kit. Psychiatric diagnoses were made according to DSM-IV criteria. Severity of major depression was assessed by the 17-item Hamilton Depression Rating Scale. Using analysis of covariance with age adjustment, there were significantly low serum BDNF protein levels in depressive patients than healthy controls in women (F=7.530, p=0.007), but not in men. Additionally, changes in serum BDNF protein levels were significantly increased in 79 patients taking antidepressants during a period of 4 weeks (t=2.116, p=0.038), especially in 61 women (t=2.542, p=0.014). Age-adjusted ANCOVA revealed no significant differences in serum BDNF protein levels between 58 responders and 21 non-responders (F=0.008, P=0.928). In responders, there were significantly increased changes in serum BDNF protein levels in 44 women (t=2.501, p=0.016), but not in 14 men (t=-0.767, p=0.457). These analytical results suggest that low serum BDNF may play an important role in depressive women and antidepressant treatment significantly increase serum BDNF. However, further studies of larger populations are necessary to confirm these results and further elucidate the effects of different classes of antidepressants on serum BDNF protein levels.     

Maternal serum concentrations of BDNF and depression in the perinatal period

There is accumulating evidence that a deficiency in brain-derived neurotrophic factor (BDNF) plays a critical role in the pathophysiology of depression. This is in line with the postulate that low BDNF levels in serum are associated with depression. However, the regulation of maternal BDNF serum levels in the perinatal period, and its relationship to maternal depression is unknown. In this study, serum BDNF concentrations were measured in 40 pregnant (follow-up: 30th and 37th week of gestation, 1 week and 8 weeks after childbirth) and 40 non-pregnant women (20-40 years old). The Edinburgh Postnatal Depression Scale (EPDS) was assessed in all subjects at all time points. Maternal serum levels of BDNF were markedly decreased, both before and after childbirth (median: <30% of non-pregnant controls). BDNF correlated with decreased Serotonin (5-HT) levels in serum (r>0.6 and p<0.001 at all time points). In contrast, there was no association with altered estrogen, progesterone, dehydroepiandrosterone or cortisol concentrations in serum. There were significantly higher cortisol levels in cases of maternal depression (EPDS scores>9 points) than in cases without depression. There was a trend to a decrease of BDNF and 5-HT levels in cases of maternal depression (as compared to cases without depression), but this was not significant. In conclusion, we demonstrate that women display markedly decreased BDNF serum levels before and after childbirth. This phenomenon might reflect an increased risk for the development of mood disorders in the perinatal period. However, the individual serum concentration of BDNF alone did not predict maternal depression in our study.     

A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia

A meta-analysis study reported serum brain-derived neurotrophic factor (BDNF) levels as a potential biomarker for schizophrenia. However, at the time, commercially available human ELISA kits were unable to distinguish between pro-BDNF (precursor BDNF) and mature BDNF, because of limited antibody specificity. Here, we used new ELISA kits, to examine serum levels of mature BDNF and matrix metalloproteinase-9 (MMP-9), which converts pro-BDNF to mature BDNF in schizophrenia. Sixty-three patients with chronic schizophrenia and 52 age- and sex-matched healthy controls were enrolled. Patients were evaluated using the Brief Psychiatry Rating Scale, the Scale for the Assessment of Negative Symptoms (SANS) and neuropsychological tests. Neither serum mature BDNF nor MMP-9 levels differed between patients and controls. In male subgroups, serum MMP-9 levels of smoking patients were higher than those of non-smoking patients, but this was not observed in male controls or the female subgroup. In patients, serum mature BDNF levels were associated with SANS total scores and the Information subtest scores of the Wechsler Adult Intelligence Scale Revised (WAIS-R), while serum MMP-9 levels were associated with smoking and category fluency scores. These findings suggest that neither mature BDNF nor MMP-9 is a suitable biomarker for schizophrenia, although further studies using large samples are needed.     

脑小血管病患者运动障碍与血清IMA LP-PLA2 BDNF水平的相关性研究

目的分析脑小血管病(CSVD)患者运动障碍与血清缺血修饰清蛋白(IMA)、脂蛋白磷脂酶A2(Lp-PLA2)、脑源性神经营养因子(BDNF)的相关性。方法选取郑州大学第一附属医院2019-01—2020-01收治的CSVD患者82例,纳入脑血管病组,另选取同期体检健康者80例为对照组,比较2组血清IMA、Lp-PLA2、BDNF水平。脑血管病组根据有无发生运动障碍分为运动障碍组与非运动障碍组,比较2组血清IMA、Lp-PLA2、BDNF水平及其他可能影响运动功能的因素。采用Logistic回归分析明确CSVD患者运动障碍的独立影响因素,Pearson相关性分析法评价CSVD患者运动障碍简式Fugl-Meyer(FM)运动功能评定量表评分与血清IMA、Lp-PLA2、BDNF水平的相关性。结果脑血管病组血清IMA、Lp-PLA2水平高于对照组,血清BDNF水平低于对照组,差异有统计学意义(P<0.05)。运动障碍组颈动脉粥样硬化占比及血清IMA、Lp-PLA2、Hcy水平高于非运动障碍组,血清BDNF水平低于非运动障碍组,差异有统计学意义(P<0.05)。Logistic回归分析证实颈动脉粥样硬化、血清IMA、Lp-PLA2、BDNF、Hcy水平均是CSVD患者发生运动障碍的独立影响因素(P<0.05)。Pearson相关性分析提示FM评分与血清IMA、Lp-PLA2呈负相关(r=-0.756、-0.670,P<0.05),与血清BDNF水平呈正相关(r=0.602,P<0.05)。结论CSVD患者血清IMA、Lp-PLA2、BDNF水平异常,且是CSVD患发生运动障碍的独立影响因素,FM量表评分与血清IMA、Lp-PLA2水平呈正相关,与BDNF水平呈负相关。     

重复经颅磁刺激对首发精神分裂症患者血清脑源性神经营养因子的影响

目的分析高频重复经颅磁刺激(rTMS)对首发精神分裂症患者血清脑源性神经营养因子(BDNF)的影响。方法选取82例以阴性症状为主的首发精神分裂症患者,使用随机数表将82例患者分为对照组41例和观察组41例,2组均使用常规药物治疗,观察组同时予以真刺激治疗,对照组予以假刺激治疗,对比2组治疗结果。结果治疗4周后观察组PANSS(阳性和阴性症状量表)总分、阴性症状评分、一般病理评分及血清BDNF浓度均优于治疗前,且优于对照组(P0.05);对照组PANSS总分、阴性症状评分、阳性症状评分、一般病理评分及血清BDNF浓度与之前相比无明显变化(P0.05)。观察组BDNF浓度变化与PANSS总分及各因子的变化无明显相关性(P0.05)。结论rTMS可显著增加首发精神分裂症患者的血清BDNF水平,但血清BDNF水平变化与其临床症状的改善无明显相关性。     

抑郁症患者自杀行为与血清脑源性神经营养因子水平的关系

目的:探讨血清脑源性神经营养因子(BDNF)水平与抑郁症患者自杀行为之间的关系.方法:采用酶联吸附反应方法对有自杀行为的21例抑郁症患者(自杀组)、无自杀行为的52例抑郁症患者(非自杀组)以及80例正常人(对照组)血清的BDNF进行检测,应用汉密尔顿抑郁量表(HAMD)对抑郁症患者的抑郁症状进行评定. 结果:抑郁症患者...